Core Viewpoint - The company plans to acquire 100% of Nameixin (Shanghai) Biotechnology Co., Ltd. through a three-phase investment strategy, with a total consideration of approximately 630 million yuan, marking a strategic shift towards mRNA vaccine innovation [1] Group 1: Acquisition Details - The acquisition will be executed in three phases, with the first phase involving a cash investment of 120 million yuan to secure approximately 27.27% equity and governance control [3] - The deal is structured with strict milestone conditions tied to the clinical progress of the RSV mRNA vaccine and HPV therapeutic vaccine, effectively managing short-term risks while enabling long-term collaborative growth [3] Group 2: Company Profile and Technology - Nameixin was established in 2021 and focuses on the research and development of mRNA vaccines and drugs, having built a comprehensive platform covering sequence design, delivery systems, and production processes [2] - The company has developed a leading technology system that includes AI-driven antigen design, proprietary mRNA optimization processes, and advanced lipid nanoparticle delivery methods [2] - Nameixin's first RSV mRNA freeze-dried vaccine received Phase I clinical approval by the end of 2024, marking a significant technological breakthrough and addressing global cold chain storage challenges [2] Group 3: Financial Projections - Revenue forecasts for the company are projected at 1.199 billion yuan, 1.36 billion yuan, and 1.478 billion yuan for 2025-2027, reflecting year-on-year changes of -16.23%, 13.40%, and 8.63% respectively [3] - Net profit attributable to the parent company is expected to be 212 million yuan, 327 million yuan, and 436 million yuan for the same period, with year-on-year growth rates of -46.84%, 54.49%, and 33.09% respectively [3]